CDA | Evidence Driven
CDA | Evidence Driven

trametinib

Details

Files
Generic Name:
trametinib
Project Status:
Active
Therapeutic Area:
Gynecological cancers
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0372-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​For recurrent low-grade serous ovarian cancer
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission received06-Sep-24
Review initiated09-Sep-24
Expert committee meeting (initial)30-Jan-25

Files

Proposed Scope View PDF

Related Content

Last Updated : October 23, 2024